BioSpace News Archive

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has been cleared by the U.S. Food and Drug Administration (FDA), giving millions of sufferers in the U.S. access to this innovative therapy.

BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System used in LIVE™ Therapy (Less Invasive Ventricular Enhancement).

COVAXX, a U.S. company developing UB-612, a multitope protein/synthetic peptide-based vaccine to fight COVID-19, today announced positive interim Phase 1 data from its open-label COVID-19 clinical trial conducted in Taiwan.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced a new research program for an oral glucagon-like peptide-2 (GLP-2) analog based on the Company’s platform technology

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced the company’s involvement in a recent article published in the New England Journal of Medicine.

Incoming leader to oversee fundraising to share trustworthy information about cancer for patients and caregivers as well as supporting promising early-career cancer researchers.

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the U.S. Food and Drug Administration (FDA) has granted rivoceranib (apatinib) with orphan drug designation for the treatment of adenoid cystic carcinoma (ACC),

Upsher-Smith Laboratories, LLC and the National Alliance of State Pharmacy Associations are pleased to honor the 2020 NASPA Excellence in Innovation Award recipients.

Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, today announced that APT-1011 (fluticasone propionate oral disintegrating tablet) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Eosinophilic Esophagitis (EoE), a rare, chronic allergic inflammatory disease characterized by eosinophilic infiltration of the esophagus.